Efficacy

Efficacy of Braftovi (Encorafenib) in Treating Skin Cancer

Braftovi, known generically as encorafenib, is a medication specifically indicated for the treatment of certain types of skin cancer. It is most commonly used for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. Encorafenib is part of a class of drugs known as BRAF inhibitors, which work by targeting and inhibiting the activity of the mutated BRAF protein that can lead to cancer cell growth.

Clinical trials have demonstrated the efficacy of encorafenib in treating melanoma with BRAF mutations. When used in combination with another medication called binimetinib, a MEK inhibitor, encorafenib has been shown to significantly improve progression-free survival compared to treatment with BRAF inhibitor vemurafenib alone. This combination therapy has also been associated with a higher overall response rate, meaning that more patients experienced a reduction in tumor size.

Efficacy of Libtayo (Cemiplimab) in Treating Skin Cancer

Libtayo, with the generic name cemiplimab, is a relatively new medication approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. Cemiplimab is a type of immunotherapy known as a PD-1 blocker. It works by enhancing the body's immune response against cancer cells.

In clinical studies, Libtayo has shown significant efficacy in treating advanced CSCC. The results have indicated a robust response rate, with a considerable proportion of patients experiencing a reduction in tumor size. Some patients achieved complete remission. Additionally, cemiplimab has been associated with durable responses, meaning that the effects of the treatment are long-lasting for many patients. The drug's approval marked a significant advancement in the treatment options available for CSCC, which is the second most common form of skin cancer.